7th Annual Atlanta
Lung Cancer Symposium

In association with

Media: Webcast Estimated time to complete activity: 7 hours Release Date: May 6, 2010 \| Expiration Date: May 5, 2011 This activity is supported by educational grants from Covidien, Genentech BioOncology & OSI Oncology, and Lilly USA, LLC

Introduction

Significant improvements have occurred in the management of lung cancer over the past decade. One of the most widely studied approaches to the field of cancer, particularly lung cancer, is treatment strategies incorporating new agents and novel combinations. Despite these advances, long-term survival benefit has remained elusive. Healthcare professionals caring for patients with lung cancer need to understand the basis for treatment approaches likely to change clinical practice in the next few years, as well as the preclinical and clinical data supporting the development and integration of these therapies into practice. Join the experts for this didactic presentation combined with discussions on controversial topics in lung cancer management.

Chairs

Rodolfo E. Bordoni, MD
Chairman, Research and Therapeutics
Georgia Cancer Specialists
Chairman, Department of Medicine
WellStar Kennestone Hospital
Atlanta, Georgia
Bio

Fadlo R. Khuri, MD
Roberto C. Goizueta Distinguished Professor and Chair
Department of Hematology and Medical Oncology
Deputy Director for Clinical and Translational Research
Emory University
Winship Cancer Institute
Atlanta, Georgia
Bio

Faculty

Chandra P. Belani, MD
Miriam Beckner Distinguished Professor of Medicine
Penn State Milton S. Hershey Medical Center
Penn State College of Medicine
Deputy Director, Penn State Cancer Institute
Hershey, Pennsylvania
Bio

Robert J. Cerfolio, MD, FACS, FCCP
Professor of Surgery
Chief of the Section of Thoracic Surgery
University of Alabama at Birmingham
Birmingham, Alabama
Bio

Walter J. Curran Jr, MD
Executive Director, Winship Cancer Institute
of Emory University
Professor and Chairman, Department of Radiation Oncology
Emory University School of Medicine
Atlanta, Georgia
Bio

Edward S. Kim, MD
Associate Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Bio

Mark G. Kris, MD
Chief, Thoracic Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan-Kettering Cancer Center
Weill Medical College of Cornell University
New York, New York
Bio

Harvey I. Pass, MD
Professor of Surgery and Cardiothoracic Surgery
Director, Division of Thoracic Surgery and
Thoracic Oncology
New York University Langone Medical Center
and Cancer Center
New York University School of Medicine
New York, New York
Bio

Suresh S. Ramalingam, MD
Associate Professor of Hematology-Oncology
Director of the Division of Medical Oncology
Chief of Thoracic Oncology
Emory University School of Medicine
Emory Winship Cancer Institute
Atlanta, Georgia
Bio

Alice T. Shaw, MD, PhD
Attending Physician, Thoracic Oncology
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Bio

Michael J. Thun, MD, MS
Vice President Emeritus, Epidemiology and
Surveillance Research
American Cancer Society
Atlanta, Georgia
Bio

William D. Travis, MD
Attending Thoracic Pathologist
Department of Pathology
Memorial Sloan-Kettering Cancer Center
New York, New York
Bio

Learning Objectives
Upon completion of this educational activity, participants should be better able to:

Describe the most current advances for the diagnosis and staging of patients with lung cancer
Describe the rationale for the development and integration of new therapeutic approaches in lung cancer
Discuss the clinical implications of the results from pivotal clinical trials that have impacted the use of new approaches and strategies for the treatment of NSCLC
Review ongoing clinical trial designs of novel surgical, radiotherapeutic, and chemotherapeutic treatment strategies for the management of NSCLC
Discuss supportive care issues and side effect management required for patients with lung cancer

Target Audience
The target audience for this educational initiative includes medical oncologists and related professionals caring for patients with lung cancer; pathologists, pulmonologists, oncology pharmacists, oncology nurses, and case managers are also invited to attend.

ACCREDITATION INFORMATION

PHYSICIAN CONTINUING EDUCATION
Accreditation Statement
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Educational Concepts Group, LLC designates this continuing education activity for 7.0 contact hour(s) (0.7 CEUs) (UAN 0199-0000-10-015-HO1-P).

TYPE OF ACTIVITY: Knowledge-based

Method of Participation
There are no fees for participating and receiving CME/CE credit for this activity. During the period May 6, 2010 through May 5, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME/CE Credit
A statement of credit will be issued only upon successful completion of the evaluation and post-test with a score of 70% or better. Your statement of credit will be available online at www.educationalconcepts.net.

Disclosure of Financial Relationships With Any Commercial Interest
As a sponsor accredited by the ACCME, it is the policy of ECG to require that everyone who is in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest and identify and resolve all conflicts of interest prior to the educational activity. The ACCME defines “relevant financial relationships” as any amount occurring within the past 12 months.

Faculty who refuse to disclose relevant financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. For an individual with no relevant financial relationship(s), the participants must be informed that no relevant financial relationship(s) exist.

If ECG determines that a potential conflict of interest exists as a result of a personal financial relationship, mechanisms will be instituted to resolve this conflict prior to the activity.

In addition, faculty members are expected to disclose discussion of an unlabeled use of a commercial product, or an investigational use not yet approved for any purpose. ECG is committed to providing learners with high-quality, unbiased, and state-of-the-art education.

The following faculty members have declared relevant financial relationships:

Rodolfo E. Bordoni, MD – Co-chair	Grants/Research Support Consultant Fees	Genzyme Corporation Lilly USA, LLC, Genentech, Inc.
Fadlo R. Khuri, MD – Co-chair	Consultant Fees	Amgen, Inc, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline
Chandra P. Belani, MD	Consultant Fees	Lilly USA, LLC
Robert J. Cerfolio, MD, FACS, FCCP	Consultant Fees Speakers’ Bureau	Medela, NeoMend Covidien, E Plus Healthcare LLC, Medela, Oncotech, Inc, Precision Therapeutics, Inc
Walter J. Curran Jr, MD	Consultant Fees	Amgen, Inc, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline
Edward S. Kim, MD	Grants/Research Support Consultant Fees Speakers’ Bureau	Genentech BioOncology, Lilly USA, LLC, OSI Pharmaceuticals, Inc Genentech BioOncology, Lilly USA, LLC Genentech BioOncology
Mark G. Kris, MD	Consultant Fees	AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer Inc
Harvey I. Pass, MD	No financial relationships to disclose
Suresh S. Ramalingam, MD	Consultant Fees	Astellas Pharma, Inc, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, Syndax Pharmaceuticals, Inc
Alice T. Shaw, MD, PhD	Consultant Fees	Pfizer Inc
Michael J. Thun, MD, MS	No financial relationships to disclose
William D. Travis, MD	No financial relationships to disclose

ECG has declared it receives educational grants from pharmaceutical industry and other commercials sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

Acknowledgement of Commercial Support
This activity is supported by educational grants from Covidien, Genentech BioOncology & OSI Oncology, and Lilly USA, LLC.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

Disclosure of Off-label Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Continuing Medical Education
For further information, please contact
Educational Concepts Group, LLC | 1300 Parkwood Circle SE | Suite 325 | Atlanta, GA 30339 | Phone: 1.770.933.1681 | Fax: 1.770.933.1692 | www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.